AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Andrey A. Ivashchenko, Kirill A. Dmitriev, Natalia V. Vostokova, Valeria N. Azarova, Andrew A. Blinow, Alina N. Egorova, Ivan G. Gordeev, Alexey P. Ilin, Ruben N. Karapetian, Dmitry V. Kravchenko, Nikita V. Lomakin, Elena A. Merkulova, Natalia A. Papazova, Elena P. Pavlikova, Nikolay P. Savchuk, Elena N. Simakina, Tagir A. Sitdekov, Elena A. Smolyarchuk, Elena G. Tikhomolova, Elena V. Yakubova, Alexandre V. Ivachtchenko
doi: https://doi.org/10.1101/2020.07.26.20154724

Article Information

doi 
https://doi.org/10.1101/2020.07.26.20154724
History 
  • August 5, 2020.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Andrey A. Ivashchenko1,
  2. Kirill A. Dmitriev2,
  3. Natalia V. Vostokova3,
  4. Valeria N. Azarova3,
  5. Andrew A. Blinow4,
  6. Alina N. Egorova3,
  7. Ivan G. Gordeev5,
  8. Alexey P. Ilin6,
  9. Ruben N. Karapetian7,
  10. Dmitry V. Kravchenko6,
  11. Nikita V. Lomakin8,
  12. Elena A. Merkulova3,
  13. Natalia A. Papazova9,
  14. Elena P. Pavlikova10,
  15. Nikolay P. Savchuk11,
  16. Elena N. Simakina12,
  17. Tagir A. Sitdekov2,
  18. Elena A. Smolyarchuk13,
  19. Elena G. Tikhomolova14,
  20. Elena V. Yakubova4 and
  21. Alexandre V. Ivachtchenko11,*
  1. 1ChemRar High-Tech Center, Khimki, Moscow region, Russian Federation
  2. 2Russian Direct Investment Fund, Moscow, Russian Federation
  3. 3IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation
  4. 4Chromis LLC, Skolkovo Innovative Centre, Moscow, Russian Federation
  5. 5City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian Federation
  6. 6Department of Chemistry and Technology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation
  7. 7Department of Biology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation
  8. 8Central Clinical Hospital with Polyclinic, Moscow, Russian Federation
  9. 9Department of finished dosage forms, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation
  10. 10Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation
  11. 11Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation
  12. 12Clinical Hospital No.1, Smolensk, Russian Federation
  13. 13First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation
  14. 14Infectious clinical hospital No. 2, Nizhny Novgorod, Russian Federation
  1. ↵*Correspondence: Alexandre V. Ivachtchenko e-mail: av{at}chemdiv.com;, Natalia V. Vostokova e-mail: nv{at}ipharma.ru
Back to top
Posted August 05, 2020.
Download PDF

Supplementary Material

Data/Code
Email
AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Andrey A. Ivashchenko, Kirill A. Dmitriev, Natalia V. Vostokova, Valeria N. Azarova, Andrew A. Blinow, Alina N. Egorova, Ivan G. Gordeev, Alexey P. Ilin, Ruben N. Karapetian, Dmitry V. Kravchenko, Nikita V. Lomakin, Elena A. Merkulova, Natalia A. Papazova, Elena P. Pavlikova, Nikolay P. Savchuk, Elena N. Simakina, Tagir A. Sitdekov, Elena A. Smolyarchuk, Elena G. Tikhomolova, Elena V. Yakubova, Alexandre V. Ivachtchenko
medRxiv 2020.07.26.20154724; doi: https://doi.org/10.1101/2020.07.26.20154724
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area